December 9, 2013

Kolltan licenses antibodies from founder

New Haven biopharma Kolltan Pharmaceuticals said it has licensed antibody technology developed by one of its founders and a member of its scientific advisory board.

The so-called anti-KIT receptor tyrosine kinase antibodies were developed in the labs of Joseph Schlessinger at Yale University — a Kolltan founder — and Sachdev Sidu, a geneticist at the University of Toronto and Kolltan adviser.

Terms of the deal were not disclosed.

Free E-Newsletters

Sign up now for our daily and weekly
e-newsletters! Click Here

Today's Poll Should Connecticut disclose the recipients of its economic development incentives?<>
Most Popular on Facebook
Copyright 2017 New England Business Media